Focus: Arcutis is a public dermatology-focused biotech company founded in 2016, headquartered in Westlake Village, CA, with a single commercial product (ZORYVE) generating $60M in FY2025 revenue.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
High-risk, high-reward opportunity for risk-tolerant professionals betting on ZORYVE market adoption; viability depends entirely on commercial execution and near-term capital raise.
Help build intelligence for Arcutis Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Arcutis Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product with 15-fold revenue growth YoY and recent FDA approval for infants, establishing market foothold and expansion potential through pediatric label.
Alternative formulation with earlier LOE date (2037) suggesting potential lifecycle management strategy or different indication focus.
The Bull Case For Arcutis Biotherapeutics (ARQT) Could Change Following FDA Acceptance Of Infant ZORYVE sNDA - simplywall.st
The Bull Case For Arcutis Biotherapeutics (ARQT) Could Change Following FDA Acceptance Of Infant ZORYVE sNDA simplywall.st
Arcutis Biotherapeutics (ARQT) Following FDA Acceptance For ZORYVE Is The Upside Still There - simplywall.st
Arcutis Biotherapeutics (ARQT) Following FDA Acceptance For ZORYVE Is The Upside Still There simplywall.st
Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy? - simplywall.st
Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy? simplywall.st
Arcutis wins FDA review for ZORYVE in infants as young as 3 months - Stock Titan
Arcutis wins FDA review for ZORYVE in infants as young as 3 months Stock Titan
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? - The Motley Fool
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? The Motley Fool
8-K Filing: PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648) — EX-99.1
EX-99.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo